Vitality Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing the cannabinoid pharmaceutical prodrugs also known as cannabosides. The Company utilizes its enzymatic bioprocessing technologies to discover its cannabosides are cannabinoid-glycoside prodrugs. The Companyâ€™s cannabosides products include glycosylated tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV) and cannabinol (CBN). Its THC-glycoside (VBX-100) prodrug is developed for the treatment of gastrointestinal diseases, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD is a frequently chronic inflammatory condition where parts of the digestive system become inflamed from an overactive immune response. IBS is a functional gastrointestinal disorder that commonly affects the large intestine and is characterized by abdominal cramping, diarrhea, constipation and pain.
Number of employees : 3 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Joseph E. Loconti ||13,153,063||
|Edward F. Feighan ||2,690,917||
|Michael Cavanaugh ||879,791||
|KLCM Advisors, Inc. ||148,000||
|Brandon Zipp ||64,000||
|Richard McKilligan ||10,000||
|FNY Capital Management LP ||4,000||
|CapFinancial Partners LLC ||3,440||
|Steward Partners Investment Advisory LLC ||2,400||
|First National Bank of Mount Dora Trust Services ||1,000||
|Company contact information|
Vitality Biopharma, Inc.
1901 Avenue of the Stars
Los Angeles, CA 90067
Phone : +1.530.231.7800
Web : http://www.vitality.bio
Sector Bio Therapeutic Drugs